Myocardial Infarction News and Research

RSS

$Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction$

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

From AstraZeneca 12 Dec 2022

New 'heart attack on a chip' could serve as a testbed to develop personalized medicines

Researchers at the University of Southern California Alfred E. Mann Department of Biomedical Engineering have developed a "heart attack on a chip," a device that could one day serve as a testbed to develop new heart drugs and even personalized medicines.

7 Dec 2022

Enrollment in Medicare Advantage not associated with higher rate of heart attack survival

Nearly half of Americans with Medicare now get their health insurance coverage through a private company that takes part in the federal government's Medicare Advantage program.

7 Dec 2022

Large COVID vaccination study found that thrombosis and thrombocytopenia are very rare complications

Researchers determine the rates of thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia following COVID-19 vaccination and infection.

28 Nov 2022

Cryo-electron tomography helps visualize platelet deformation due to SARS-CoV-2 spike protein

Researchers used cellular cryo-electron tomography (cryo-ET) to demonstrate the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in coronavirus disease 2019 (COVID-19)-triggered severe coagulopathies.

28 Nov 2022

The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C

Researchers evaluated the serological responses elicited by COVID-19 vaccinations in children who developed MIS-C following a previous SARS-CoV-2 infection.

23 Nov 2022

Shingles linked with higher long-term risk of major cardiovascular event

A new study by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, demonstrated that shingles, also known as herpes zoster, is associated with an almost 30% higher long-term risk of a major cardiovascular event such a stroke or heart attack.

22 Nov 2022

Does influenza vaccination reduce death and vascular events in patients with heart failure?

Researchers conducted a placebo-controlled, double-blind clinical trial to assess whether influenza vaccination effectively reduced vascular events and mortality among patients with heart failure.

21 Nov 2022

Study shows biological link between muscle weakness and acceleration in biological age

Everyone ages at a different pace. That's why two 50-year-olds, despite living the same number of years, may have different biological ages – meaning that a host of intrinsic and extrinsic factors have caused them to age at varying paces with different levels of risk for disease and early death.

10 Nov 2022

Rheumatoid arthritis patients taking opioids have twice the risk of venous thromboembolism

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, found that adult RA patients starting opioids had twice the risk of venous thromboembolism (VTE) compared to patients starting nonsteroidal anti-inflammatory drugs (NSAIDs).

8 Nov 2022

U.S. COVID-19 vaccine safety surveillance results for the over 65s

In a recent study posted to the medRxiv* server, researchers conducted near real-time safety monitoring in the United States (US) elderly population for 14 safety outcomes weekly following the coronavirus disease 2019 (COVID-19) vaccination

7 Nov 2022

Heart attack patients without modifiable risk factors are common and fare better, study finds

A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk factors, but researchers say it remains difficult to identify those at risk for an event before it happens.

6 Nov 2022

New risk analysis strategy benefits chest pain patients compared to the usual testing approach

A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.

6 Nov 2022

Blood clotting protein found to play a new role in repairing damaged blood vessels

Research by RCSI University of Medicine and Health Sciences has discovered a new role for the blood clotting protein, von Willebrand Factor (VWF), that could lead to the development of new treatments for patients with inflammatory and blood clotting disorders.

3 Nov 2022

Effect of marital stress on heart attack recovery is detrimental

In a recent study soon to be presented at the American Heart Association (AHA) Scientific Sessions 2022*, researchers examined the adverse effects of marital stress (MS) on recovery from acute myocardial infarction (AMI).

2 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

Study identifies a root cause of chronic heart failure following a heart attack

A multi-institution study led by Rohan Dharmakumar, PhD, of Indiana University School of Medicine, has identified that iron drives the formation of fatty tissue in the heart and leads to chronic heart failure in about fifty percent of heart attack survivors.

1 Nov 2022